In breast cancer, CD68+ Mφs can be categorized into two subgroups based on thymidine phosphorylase (TP) that are associated with strikingly different prognosis: a TP+ Mφ group that shows a poor prognosis and a TP− Mφ group that shows a good prognosis [12]. The gene discussed is TYMP; the disease is breast carcinoma.